Soleno Therapeutics, Inc. (SLNO) has been on a downward spiral lately with significant selling pressure. After declining 21.7 ...

Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face ...

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $100 and keeps a Buy rating on the shares. The firm says ...

Soleno Therapeutics Inc (NASDAQ:SLNO) stock fell 13% Friday morning following a short report from Scorpion Capital that raised serious concerns about the company’s recently approved Prader-Willi ...

Recent health news highlights Britain's decision not to support the bioethanol industry, Berkshire Hathaway's investment in ...

Soleno has not yet completed its financial close and review processes for the three months ended June 30, 2025. The review of Soleno’s financial statements for the three months ended June 30 ...

Analysts are estimating that Soleno Therapeutics will report an earnings per share (EPS) of $-0.53. The market awaits Soleno ...

About Soleno Therapeutics, Inc. Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company recently submitted an NDA to the ...

Scorpion Capital disclosed a short position in Soleno Therapeutics on Friday, citing issues with the drugmaker's recently approved treatment Vykat XR, sending its shares slumping 15% in premarket ...

Present Market Standing of Soleno Therapeutics Currently trading with a volume of 1,138,044, the SLNO's price is up by 1.58%, now at $58.12. RSI readings suggest the stock is currently may be ...

Shares of Soleno Therapeutics (NASDAQ: SLNO) were skyrocketing 39.8% higher as of 10:51 a.m. ET on Monday. The huge gain came after the clinical-stage biopharmaceutical company announced the U.S ...

Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 Provided by GlobeNewswire Jul 10, 2025, 3:00:37 AM ...